A Simple and Fast UHPLC–MS-MS Assay for Rapid Determination of Vilazodone in Plasma Sample
Bajrai, Muzaffar Iqbal, Essam Ezzeldin, Khalid A. Al-Rashood and Amal A. . 2015
Vilazodone is a novel antidepressant agent, approved by the US Food
and Drug Administration (US FDA) for the treatment of major depressive
disorder. In this study, a fast sensitive ultra-high performance liquid
chromatography–tandem mass spectroscopy method was
developed and validated for the determination of vilazodone in
human plasma. After a simple protein precipitation by acetonitrile,
both vilazodone and risperidone (internal standard, IS) were separated
on an Acquity UPLC BEHTM C18 column (50 3 2.1 mm, 1.7 mm).
An isocratic mobile phase of acetonitrile:10 mM ammonium acetate
(80:20, v/v) was used at the 0.3 mL/min flow rate. Both vilazodone
and IS were eluted at 0.44 and 0.47 min, respectively, having a run
time of 1.0 min. Detection and quantification were performed using
an electrospray ionization source in positive mode by multiple reaction
monitoring. The precursor to product ion transitions were monitored
at m/z 442.19 > 154.99 for vilazodone and m/z 411.18 > 191.07
for IS, respectively. The standard curve (0.40–500 ng/mL) was found
to be linear with a lower limit of quantification 0.40 ng/mL. All validation
results were found to be within acceptable limits as per guidelines
for bioanalytical method validation (US FDA and European
Medicines Agency). To the best of our knowledge, this is the first
fully validated assay for the determination of vilazodone in human
plasma and was successfully applied to an oral pharmacokinetic
study in rats.
